Dogwood Therapeutics, Inc. (DWTX)
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$34.3M
- Total assets
- $90.2M
- Market cap
- $50.4M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $28.0M
- Operating income
- -$28.0M
- Income tax
- $221.1K
- Net income
- -$34.3M
- EPS (basic)
- $-7.13
- EPS (diluted)
- $-7.13
Balance sheet
- Total assets
- $90.2M
- Current assets
- $8.4M
- Total liabilities
- $15.3M
- Current liabilities
- $3.1M
- Shareholders’ equity
- $74.9M
Cash flow
- Operating cash flow
- -$15.6M
- Investing cash flow
- $8.3M
- Financing cash flow
- $7.3M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $50.4M
- EPS (diluted)
- $-7.13
- Shares outstanding
- 33.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 17, 2020
Dogwood Therapeutics, Inc. (DWTX) Stock Price
- Reported a net loss of $34.3M.
- Trading 81% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Dogwood Therapeutics, Inc..
Write a review
News about Dogwood Therapeutics, Inc.
News & sentiment via Polygon.io
Dogwood Therapeutics, Inc.: frequently asked questions
Is Dogwood Therapeutics, Inc. an American company?
Dogwood Therapeutics, Inc. is a US-based company headquartered in Alpharetta, Georgia, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Dogwood Therapeutics, Inc. headquartered?
Dogwood Therapeutics, Inc. is headquartered in Alpharetta, Georgia, United States.
Is Dogwood Therapeutics, Inc. publicly traded?
Yes — Dogwood Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol DWTX on the NASDAQ.
What does Dogwood Therapeutics, Inc. do?
Dogwood Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
